文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

每日奥替尼啶消毒沐浴对ICU获得性菌血症和ICU获得性多重耐药菌的影响:一项多中心、整群随机、双盲、安慰剂对照、交叉研究

EFFECT of daily antiseptic bathing with octenidine on ICU-acquired bacteremia and ICU-acquired multidrug-resistant organisms: a multicenter, cluster-randomized, double-blind, placebo-controlled, cross-over study.
PubMed 文献 · Intensive Care Med · 2024-10-17
一句话结论在德国44个ICU的交叉研究中,奥替尼啶消毒沐浴使ICU获得性原发性菌血症风险降低17%(调整HR 0.83),对ICU获得性多重耐药菌无显著影响(调整HR 0.98)。

该研究为多中心、整群随机、双盲、安慰剂对照、交叉研究,在德国23家医院的44个ICU进行,比较奥替尼啶浸渍毛巾与安慰剂毛巾沐浴,每个ICU自身前后两个12个月时段对比。共分析104,039例ICU episodes(93,438例患者)和712,784份微生物检测结果,检出1508例ICU获得性原发性菌血症和1871例ICU获得性MDRO。奥替尼啶沐浴使ICU获得性原发性菌血症风险降低17%(调整HR 0.83,95%CI 0.75-0.92,p=0.0003),主要影响凝固酶阴性葡萄球菌(53%)和肠球菌(17%);对ICU获得性MDRO无干预效应(调整HR 0.98,95%CI 0.83-1.15),ICU内干预效应异质性大。作者认为奥替尼啶消毒沐浴可能有效预防ICU获得性原发性菌血症,尤其是革兰阳性菌和常见皮肤共生菌所致者。

要点

  • 奥替尼啶消毒沐浴使ICU获得性原发性菌血症风险降低17%(调整HR 0.83,95%CI 0.75-0.92,p=0.0003),效应在所有参与ICU中一致。
  • 该减少主要涉及凝固酶阴性葡萄球菌(53%)和肠球菌(17%)。
  • 对ICU获得性MDRO无干预效应(调整HR 0.98,95%CI 0.83-1.15),ICU内干预效应异质性大。
  • 研究纳入104,039例ICU episodes(93,438例患者),检出1508例ICU获得性原发性菌血症和1871例ICU获得性MDRO。
  • 作者认为奥替尼啶消毒沐浴可能有效预防ICU获得性原发性菌血症,尤其是革兰阳性菌和常见皮肤共生菌所致者。

适用人群与场景

  • 德国23家医院44个ICU的成人ICU患者,共104,039例ICU episodes(93,438例患者)。

处置流程与药物剂量

  • 使用奥替尼啶浸渍毛巾与安慰剂毛巾进行每日沐浴,每个ICU自身前后两个12个月时段交叉对比。

研究设计与关键结果

  • 研究类型:多中心、整群随机、双盲、安慰剂对照、交叉研究;在德国23家医院44个ICU进行,比较奥替尼啶浸渍毛巾与安慰剂毛巾沐浴,每个ICU自身前后两个12个月时段对比。
  • 共分析104,039例ICU episodes(93,438例患者)和712,784份微生物检测结果,检出1508例ICU获得性原发性菌血症和1871例ICU获得性MDRO。
  • 奥替尼啶沐浴预防ICU获得性原发性菌血症,风险降低17%(调整HR 0.83,95%CI 0.75-0.92,p=0.0003),效应在所有参与ICU中一致。
  • 该减少主要涉及凝固酶阴性葡萄球菌(53%)和肠球菌(17%)。
  • 对ICU获得性MDRO无干预效应(调整HR 0.98,95%CI 0.83-1.15),ICU内干预效应异质性大。

证据类型、等级与局限

  • 证据类型:多中心、整群随机、双盲、安慰剂对照、交叉研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为奥替尼啶消毒沐浴可能有效预防ICU获得性原发性菌血症,尤其是革兰阳性菌和常见皮肤共生菌所致者。
  • 研究未显示奥替尼啶消毒沐浴对ICU获得性MDRO有干预效应(调整HR 0.98,95%CI 0.83-1.15)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Antiseptic bathing has garnered attention in an effort to reduce hospital-acquired infections. Previous studies have shown the efficacy of antiseptic bathing in high-risk environments, such as intensive care units (ICUs), using chlorhexidine. In this study we aimed to evaluate the effectiveness of octenidine as a potential alternative due to its established popularity and widespread use in Europe.

METHODS: We compared the rates of ICU-acquired primary bacteremia and ICU-acquired multidrug-resistant organisms (MDROs) in a multicenter, cluster-randomized, double-blind, placebo-controlled, cross-over study using octenidine-impregnated and placebo washcloths. On 44 ICUs in 23 hospitals throughout Germany, we compared individual ICUs with themselves over two 12-month time periods. All data were obtained digitally via hospital information systems as individual ward-movement data and microbiological test results; both endpoints were algorithmically derived.

RESULTS: 104,039 ICU episodes from 93,438 patients with 712,784 microbiological test results were analyzed, thereby detecting 1508 cases of ICU-acquired primary bacteremia and 1871 cases of ICU-acquired MDRO. Bathing with octenidine-impregnated washcloths prevented ICU-acquired primary bacteremia; a risk reduction of 17% was seen homogeneously across all participating ICUs (adjusted hazard ratio (HR) 0.83, 95% confidence interval (CI) [0.75; 0.92], p = 0.0003). This reduction affected predominantly coagulase-negative staphylococci (53%) and enterococci (17%). However, no intervention effect was seen for ICU-acquired MDROs (adjusted HR 0.98, 95% CI [0.83; 1.15]). Heterogeneity among intra-ICU intervention effects on MDRO acquisition was substantial.

CONCLUSIONS: Antiseptic bathing with octenidine may be effective in preventing ICU-acquired primary bacteremia, particularly due to Gram-positive bacteria and common skin commensals.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Schaumburg T, Köhler N, Breitenstein Y, et al. EFFECT of daily antiseptic bathing with octenidine on ICU-acquired bacteremia and ICU-acquired multidrug-resistant organisms: a multicenter, cluster-randomized, double-blind, placebo-controlled, cross-over study. Intensive Care Med. 2024. PMID: 39417875. doi:10.1007/s00134-024-07667-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。